Xilio Therapeutics (XLO) Net Income Growth (1y) (2021 - 2026)

Xilio Therapeutics (XLO) Net Income Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -0.46%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.08%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 63.48%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Xilio Therapeutics 148.60 Mn -1.70 Mn - -1.59%

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.59%
Dec 31, 2025 14.72%
Sep 30, 2025 86.56%
Jun 30, 2025 3.19%
Mar 31, 2025 21.86%
Dec 31, 2024 27.60%
Sep 30, 2024 14.61%
Jun 30, 2024 26.32%
Mar 31, 2024 25.00%
Dec 31, 2023 21.33%
Sep 30, 2023 14.79%
Jun 30, 2023 18.66%
Mar 31, 2023 -10.79%
Dec 31, 2022 -24.24%
Sep 30, 2022 35.68%
Jun 30, 2022 -7.43%
Mar 31, 2022 -28.13%
Dec 31, 2021 8.74%
Sep 30, 2021 -114.29%